Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204679 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06204679 is a Phase 1 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT06204679, a Phase 1 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
Interventions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions
- DRUG Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2024-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06204679
The ClinicalTrials.gov registry entry for NCT06204679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions is the first listed.
NCT06204679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06204679 about?
NCT06204679 is a clinical study titled "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir". This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
What is the current status of trial NCT06204679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-12-14. Estimated completion is 2024-08-25.
What interventions are being tested in trial NCT06204679?
The interventions under investigation include: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions (DRUG), Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions (DRUG), Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions (DRUG).
Who is sponsoring clinical trial NCT06204679?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.